Results 141 to 150 of about 7,987 (192)

Camrelizumab plus apatinib for immune checkpoint inhibitor-naive patients with metastatic clear cell renal cell carcinoma after first-line tyrosine kinase inhibitor treatment failure: a single-arm phase 2 trial. [PDF]

BMC Med
Cai X, Zheng X, Wang D, Huang T, Peng Y, Zhang Z, Guo S, Han H, He L, Xu W, Zhou F, Jiang L, Dong P.   +12 more
europepmc   +1 more source

Real-world study of SHR-1210 plus apatinib in the treatment of BRAF-negative mucosal melanoma: efficacy, safety and implications of precision medicine. [PDF]

Front Immunol
Zhang Y, Wang T, Lyu AQ, Zhang F, Li FH, Zhao LD, Wang ZB, Shang YM, Ma BZ, Dong XQ, Gao QL.   +10 more
europepmc   +1 more source

Synergistic Anticancer Effects of Apatinib and PD-L1 Inhibition in Breast Cancer. [PDF]

J Mammary Gland Biol Neoplasia
Han D, Xu J, Guo C.
europepmc   +1 more source

Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis. [PDF]

J Gastrointest Oncol
Long JY, Wang XH, Li YR, Huang SR, Li ZJ, Luo Y.   +5 more
europepmc   +1 more source

Antitumor Effects of Apatinib on Tongue Cancer in Patient-Derived Xenograft Models. [PDF]

Iran J Med Sci
Sun Y, Xin Y, He Y, Liu J, Hu X.
europepmc   +1 more source

Vascular plasticity in the gastric cancer environment: mechanisms, prognostic significance, and concepts of therapeutic interventions. [PDF]

Cancer Metastasis Rev
Chmiela M, Jaroniek P, Manzaneque JCR, Balcerczak E, Brzeziński M, Jeleń A, Mani S, Wosiak A, Gonciarz W.   +8 more
europepmc   +1 more source

Identification of predictive biomarkers and dose optimization for camrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma: a quantitative systems pharmacology approach. [PDF]

Front Immunol
Huang W, Tu G, Li D, Wang C, Zhou J, Jiao Z, Yang L.   +6 more
europepmc   +1 more source

Metachronous hepatocellular carcinoma after partial response of advanced intrahepatic cholangiocarcinoma treated with radiotherapy combined with apatinib and camrelizumab: a case report. [PDF]

Front Oncol
Dai Y, Chen D, Wu S, Geng Y, Chen X, Zhang N, Tan X.   +6 more
europepmc   +1 more source

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial. [PDF]

Signal Transduct Target Ther
Zhang F, Zheng Z, Zhang H, Yan X, Liu Z, Yang F, Wen J, Gan X, Wu L, Cang S, Wang H, Zhao J, Peng L, Li X, Fan Z, Shen G, Zhou Q, Zou J, Xu Y, Zhang L, Zhao M, Cai S, Hu Y.   +22 more
europepmc   +1 more source